Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | SLC10A2 | Q12908 | 3/20 | 0.39 |
| ▸ | PGK1 | P00558 | 2/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | TNF | P01375 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | G6PD | P11413 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | HK1 | P19367 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16689300 | 0.89 | SMN1; SMN2 (0.44) | SMN1; SMN2ALDH1A1KDM4ESLC10A2PGK1 | |
| SCHEMBL11209986 | 0.87 | SMN1; SMN2 (0.45) | SMN1; SMN2ALDH1A1KDM4ESLC10A2PGK1 | |
| SCHEMBL28008552 | 0.83 | SMN1; SMN2 (0.41) | SMN1; SMN2ALDH1A1KDM4ESLC10A2PGK1 | |
| SCHEMBL16689327 | 0.83 | SMN1; SMN2 (0.41) | SMN1; SMN2ALDH1A1KDM4ESLC10A2PGK1 | |
| SCHEMBL6767043 | 0.83 | SMN1; SMN2 (0.41) | SMN1; SMN2ALDH1A1KDM4ESLC10A2PGK1 | |
| SCHEMBL7652710 | 0.79 | SLC10A2 (0.40) | SMN1; SMN2ALDH1A1KDM4ESLC10A2PGK1 | |
| SCHEMBL6767322 | 0.77 | SLC10A2 (0.46) | SMN1; SMN2ALDH1A1KDM4ESLC10A2CYP3A4 | |
| SCHEMBL6764873 | 0.77 | TNF (0.44) | SMN1; SMN2ALDH1A1KDM4EHTTTNF | |
| SCHEMBL27248956 | 0.77 | PDE3B (0.42) | SMN1; SMN2ALDH1A1KDM4EPGK1MAPT | |
| SCHEMBL16689302 | 0.76 | CFD (0.47) | SMN1; SMN2ALDH1A1KDM4ETNFEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070265446-A1 | Arylamine-substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists | CONNOLLY TERRENCE J | 2007-11-15 | — | — | US | disclosed |
| US-20070265446-A1 | Arylamine-substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists | CONNOLLY TERRENCE J | 2007-11-15 | — | — | US | disclosed |
| US-7244738-B2 | Arylamine-substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists | ROCHE PALO ALTO LLC (US) | 2007-07-17 | — | — | US | disclosed |
| US-7244738-B2 | Arylamine-substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists | ROCHE PALO ALTO LLC (US) | 2007-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265446-A1 | Arylamine-substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists | ADRB1, ADRA1A, ADRA1B | SMN1; SMN2 4179/4885ALDH1A1 245/4885KDM4E 4105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.